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Since its first appearance in Wuhan, China, severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) has rapidly spread throughout the world and has be-
come a global pandemic. Several medical comorbidities have been identified as risk
factors for coronavirus disease 2019 (COVID‐19). However, it remains unclear
whether people living with human immunodefeciency virus (PLWH) are at an
increased risk of COVID‐19 and severe disease manifestation, with controversial
suggestion that HIV‐infected individuals could be protected from severe COVID‐19
by means of antiretroviral therapy or HIV‐related immunosuppression. Several cases
of coinfection with HIV and SARS‐CoV‐2 have been reported from different parts of
the globe. This review seeks to provide a holistic overview of SARS‐CoV‐2 infection
in PLWH.
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1 | INTRODUCTION
Coronavirus disease 2019 (COVID‐19) is a potentially fatal re-
spiratory illness caused by severe acute respiratory syndrome cor-
onavirus 2 (SARS‐CoV‐2), a newly identified coronavirus, which was
first recognized in December 2019 in Wuhan, Hubei Province, China
and has since rapidly spread to over 200 countries/territories/areas
and have been declared a global pandemic by the World Health
Organization (WHO).1 As at the time of writing (3 June 2020), the
total confirmed cases were 6 383 805 with 2 732 976 recoveries and
a staggering 380 384 deaths have been officially reported globally.2
The clinical spectrum of COVID‐19 is broad, and while most people
with COVID‐19 develop only mild or uncomplicated illness, especially
in the early phase of illness, 14% to 26% of infected persons develop
severe disease that requires hospitalization and oxygen support, with
some even requiring admission to an intensive care unit.3,4 Organ
dysfunction, particularly progressive respiratory failure, heart and
kidney injuries, is associated with the highest rates of mortality.5,6
Clinical evidence has shown that disease severity and mortality are
associated with older age and underlying comorbidities, such as
diabetes, hypertension, and cardiovascular disease (CVD).4,6,7 In line
with this, one of the puzzling questions in the wake of this pandemic
is “Does HIV infection increases the risk of getting and disease se-
verity of COVID‐19?.” This is important, especially in Africa, as the
region accounts for more than 70% of the global burden of human
immunodefeciency virus (HIV) infection.8 Generally, people living
with HIV (PLWH) are perceived to be at high risk of contracting
SARS‐CoV‐2, even though currently no specific information about
the risk of COVID‐19 in people with HIV is available. At the end of
2018, it was estimated that 37.9 million people globally were living
with HIV with 20.6 million (54%) in the eastern and southern Africa
region, 5.9 million in Asia and the Pacific region, 5.0 million in wes-
tern and central Africa, and 2.2 million in western and central Europe
and north America region.9 In an attempt to halt the spread of
COVID‐19, governments across the globe are shutting cities down,
restricting movements and encouraging residents to stay indoors.
Beyond the unprecedented disruption of lives, the COVID‐19 pan-
demic has severely interrupted HIV care delivery among several
other health care services globally as attention, resources and per-
sonnel have been diverted to the fight against COVID‐19.10‐12 It is
estimated that about 19% of HIV‐infected patients were unable to
get antiretroviral medications or therapy (ART) refills due to the
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pandemic. In addition, there have been reports that several HIV/
AIDS prevention and control centers globally have been converted to
COVID‐19 treatment centers, which denies HIV patients of their
ART.13‐15 This has left a greater proportion of the HIV community in
a venerable state, considering that they require regular medication to
maintain good health. Despite the potentially poor prognosis for
most patients within this category when infected with SARS‐CoV‐2,
data on HIV/SARS‐CoV‐2 co‐infection is still scarce. Herein we
summarize the global instances of SARS‐CoV‐2/HIV coinfections.
1.1 | General impact of COVID‐19 on patients
with HIV
The COVID‐19 pandemic, as well as measures taken by governments
across the world, to minimize its spread has triggered unintended
consequences in terms of HIV testing and care.16 The Euroguidelines
in Central and Eastern Europe Network Group recently found that
60% of HIV physicians simultaneously are involved in work related to
patients with COVID‐19. In the worst scenarios, they abandon their
original duties entirely and engage fully in COVID‐19 cases.17
Moreover, to compensate for the increasing numbers of recorded
cases (patients), HIV treatment facilities have been designated as
COVID 19 care centers. According to Kowalska and coworkers,
about 70% of HIV treatment facilities in central and Eastern Europe
were not functioning due to COVID‐19.17 This together with the fear
of contracting COVID‐19 have kept many patient with HIV from
accessing their usual ART. The Lancet HIV recently reported that HIV
patients in Egypt are petrified to go for their ART refills because the
only HIV treatment Center, have been converted to COVID‐19
quarantine and treatment facility.18 In the Hubei province of China,
about 64.15% of HIV patients could not have access to their ART due
to the measures imitated to curb the spread of the virus.19 As Go-
kengin et al reported, antiretrovirals are purchased and distributed
via designated clinics 20 thus, patients living outside the perimeter
could not have access to their ART. The situation is further ag-
gravated by shortage of medication as medical consignments are
stuck in procurement systems in other countries with no further
supplies able to come in.21 The pandemic has as well compromised
the psychological and emotional wellbeing of PLWH. Shiau et al22
reported that many HIV patient being managed via telephone have
indicated that they are extremely stressed, anxious, and unable to
sleep. A recent survey in China,19 revealed that 28.93% of the re-
spondents hoped they had some social and psychological support.
Therefore, these psychosocial issues have to be addressed to avoid
exacerbating adverse medical consequence among PLWH.22
2 | METHODS
SCOPUS, Web of Science, PubMed and Google Scholar were sear-
ched for relevant peer‐reviewed publications from December 2019
to 3 June 2020, using the following combination of terms: (“HIV”
AND “COVID‐19”), (“Immunodeficiency” AND “COVID‐19”) and
(“HIV” AND “Coronavirus”). The search was limited to only publica-
tions in English. Publications with information on HIV/SARS‐CoV‐2
co‐infection were manually sorted out and included in this study.
Websites of relevant organizations including WHO, CDC, and
USAIDS were also reviewed for additional information. Data on co-
infection cases were extracted and entered into Microsoft Excel.
Statistical analyses were carried out using IBM SPSS Statistics ver-
sion 25.
3 | RESULTS AND DISCUSSION
The first case of HIV/SARS‐CoV‐2 coinfection was reported in
Wuhan, China, the terminus a quo of the pandemic. Subsequent cases
of coinfection have been reported in UK, USA, Spain, Italy, Germany
and other countries (Table 1). Interestingly, only two cases of coin-
fection have been reported in the whole of the Africa continent,
notwithstanding the fact that South Africa which is at present the
epicenter of the COVID‐19 pandemic in Africa1 and home to over
close to 8 million PLWH, the largest HIV epidemic in the world.23 The
situation of Africa is probably not because less PLWH have actually
contracted COVID‐19, but more likely due to unpublished data,
taking into account the uncoordinated and poor data collection and
management in hospitals and health centers, lack of enthusiasm and
ability of most health professionals to conduct research and prepare
manuscripts for publication as well as poor collaboration between
researchers and health professionals. The region currently accounts
for just a little of 1% of global health publications 24 with a significant
part being championed by researchers from high income countries.25
Nonetheless, 378 HIV/SARS‐CoV‐2 coinfection cases have so far
been reported globally with a majority originating from UK (101
cases) and USA (122 cases). The high number of coinfection cases
from these countries however does not particularly suggest any in-
creased risk of COVID‐19 among PLWH in them. It is worth noting
that studies characterizing a larger population of patients with
COVID‐19 originated from these countries, and hence the high re-
ported cases of coinfection. Similar to that observed in the general
population, majority (72.3% of 334) of the COVID‐19 cases in PLWH
were males. While WHO earlier reported 51% of cases in China are
males, studies from UK 26 and USA 27 indicated males represent up
60% of the COVID‐19 cases. Also, among a total of 142 coinfection
cases where information on age is available, 59.9% were in the range
of 40 to 59 years (Figure 1) with 23.2% being under 40 years. Taking
into consideration studies from Italy,28 Spain,29 Turkey 30 and UK 31
that characterizes COVID‐19 in HIV cohorts (n = 12 296), the pre-
valence of HIV/SARS‐CoV‐2 coinfection is 0.98%. On the other hand,
considering reports from China,32‐34 Japan,35 Spain,36 UK,26 and
USA,27,37 PLWH account for only 0.64% of the general COVID‐19
population (n = 26, 049; see supplementary data) as compared with
16.9% to 56.6% for CVD (including hypertension), 8.2% to 33.8% for
diabetes and 1.5% to 17.7% for respiratory diseases.26,27,38 This
correlate to several studies among large populations which observed
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that PLWH made up approximately less than 1% of COVID‐19
cases.26,27 The low proportion of PLWH among patients with COVID‐
19 should, however, be interpreted with caution as it could be as a
result unyielding commitment to safety precautions (including
wearing of nose masks, hand hygiene, social distancing, etc.) by in-
dividuals with HIV to limit their exposure to the SARS‐CoV‐2, bearing
in mind their compromised immune system and the fact that even
before COVID‐19 they were at risk of a broad range of infections,
including respiratory tract infections,23 rather than protection af-
forded by HIV or ART. It could also be that less of the HIV population
is being screened for COVID‐19, looking at the fact some are not
even enthused to visit treatment centers and clinics for their ART
refills.18 In general, 214 of a total 334 coinfection cases were un-
complicated (ie, mild and moderate) cases while the remaining 35.9%
were classified as either severe or critical (complicated), requiring
oxygen therapy and/or admission to intensive care unit (Figure 2).
Among subjects with known outcomes (closed cases; n = 300) 82.3%
had recovered while the remaining (53 patients) died, thus giving an
overall case‐fatality rate of 14% among PLWH, which is more than 2
times higher than the current rate among the global population.1
However, just like the country‐specific case‐fatality ratio of COVID‐
19 in the general population, the case‐fatality rate among PLWH
differ from one country to another, ranging from as high as 27.7% in
UK to 0% in China (Figure 3). Similar to UK, the results of the analysis
indicated USA also has a high case‐fatality ratio (13.9%) among its
HIV population which is 2.4 time higher than that of the general
population (5.8%).39 Among the top five countries in terms of number
of coinfection cases reported, the case‐fatality ratio among PLWH in
Spain (3.6%) and Italy (4.3%) are lower than that recorded for the
general population, 11.3% and 14.4% respectively.39 Compared with
that of the general population of the country, the case‐fatality rate
among the HIV population in UK and Germany are almost two times
higher. Differences in mortality numbers of COVID‐19 among
countries have been attributed to several factors including differ-
ences in number of people tested, demographic characteristics,


















(n = 188) Reference
Austria 1 1 1 1 1 47
China 9 1 4 0 2 33,34,45,48‐52
Cyprus 1 NA 1 1 1 53
Germany 33 20 33 30 32 54
Italy 47 30 36 44 0 28
Japan 1 NA NA 0 0 55
Singapore 1 0 1 1 1 56
S. Africa 1 1 1 1 0 57
Spain 56 34 55 54 49 29,36
Turkey 4 1 3 0 3 30
Uganda 1 0 1 0 1 8
UK 101 6 18 17 14 26,31
USA 122 57 74 54 60 27,37,40,41,58‐62
Overall 378 151 228 203 164
Abbreviations: COVID‐19, coronavirus disease 2019; HIV, human immunodefeciency virus; NA, not
available; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
F IGURE 1 Demographic characteristics of HIV/SARS‐CoV‐2
coinfected patients
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characteristics of the healthcare system, among others.39 None-
theless, it should be noted that majority of the cases included in this
study (particularly from UK and USA) were hospitalized patients and
as such the high case‐fatality rates recorded might not be particularly
peculiar to HIV/SARS‐CoV‐2 coinfection since as much as 26% (in
UK) 26 and 21% (in USA) 27 of hospitalized patients with COVID‐19
were reported dead. Earlier reports on HIV/SARS‐CoV‐2 coinfection
suggested that PLWH do not have an increased risk of COVID‐19
and that HIV patients who are compliant to ART and have achieved
viral suppression are even less likely to have severe/complicated
COVID.28,30,37,40 From our analysis (Table 1), 228 out of 244 were on
ART before being diagnosed with COVID‐19. About 76.8% of them
were taking nucleoside reverse transcriptase inhibitors (mostly te-
nofovir and emtricitabine), 89.7% were on integrase strand transfer
inhibitors (chiefly, bictegravir and dolutegravir), 77.4% on non‐
nucleoside reverse transcriptase inhibitors (particularly rilpivirine
and efavirenz), while 33.8% were taking protease inhibitors eithers
separately or as boosters. Also, 203 out of 378 had viral load sup-
pression (<50 copies per mL) while the data on at least 90% of the
remaining were not available. Given these, it is apparent that ma-
jority of the patients in these cases were virologically suppressed on
ART. This nonetheless did not prevent progression to severe COVID‐
19 or even death in some patients. A χ2 analysis of 105 patients
whose individual information were available showed that though a
great proportion of patient with viral load <50 copies successfully
recovered (91.5% vs 81.8% of non‐virologically suppressed patients)
there is no evidence of association between viral suppression status
and severity of COVID‐19 (χ2 = 1.068; P = .302) or clinical outcome of
patients (χ2 = 1.069; P = .301). Except for only 2 out of 105, all pa-
tients where on ART (92 of whom where virologically suppressed),
F IGURE 2 Disease Severity associated
with HIV/SARS‐CoV‐2 coinfected patients
F IGURE 3 Outcome reported endpoint for
HIV/SARS‐CoV‐2 coinfected patients
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yet 22.8% of them had severe/critical COVID‐19 while nine died. This
therefore raises significant concerns over earlier suggestion that
PLWH are somewhat immune to severe cases of COVID‐19. Su-
wanwongse and Shabarek41 previous expressed similar concern
when they reported as high as 78% mortality among HIV/SARS‐CoV‐
2 coinfected patients in their facility. The main reason earlier studies
hypothesized that ART could confer protection against COVID‐19 in
PLWH was that antiviral agents, such as remdesivir, tenofovir, and
lopinavir showed antiviral activity against SARS‐CoV‐2 in vitro stu-
dies. Despite several observations that some antiviral agents some-
what improve symptoms of COVID‐19,42 at present standard ART
does not seem to shield PLWH from COVID‐19. Also, given the
profound contribution of the immune system, particularly the mas-
sive release of cytokines and chemokines, to the severity of
COVID‐19, earlier reports proposed that HIV‐related im-
munosuppression could paradoxically protect against severe mani-
festation of COVID‐19.37,43‐45 Out of 182 with individual data on
CD4 count, 106 had CD4 count ≥200 cells per µL—59.4% of whom
had CD4 > 500 cells per µL. Our analysis show an evidence of strong
association between immune suppression status (CD4 count <200 or
≥200 cells per µL) and increased severity of disease (n = 119;
χ2 = 7.772; P = .005) but not clinical outcome (n = 109; χ2 = 1.191;
P= .275). A binary regression analysis further showed that CD4 count
<200 cells per µL increases the risk of progression to severe COVID‐
19 by almost 5 (odds ratio = 4.92; 95% confidence interval, 1.48‐
16.37). About 61% of cases with CD4 <200 cells per μL had com-
plicated COVID‐19 manifestation of which two died. Thus, contrary
to earlier suggestions that coinfection patients may have mortality
benefits from HIV‐related immunosuppression, low CD4 count below
200 per µL may rather predispose them to severe forms of the dis-
ease. Two hundred and sixty‐nine of the patients were reported to be
hospitalized while 109 were reported to be outpatients. The large
number of hospitalized patients is mainly due to the fact that most of
the case and series reports considered in this paper were of in-
patients. As such we are unable to estimate if coinfection influence
the hospitalization rate. Currently several medical comorbidities in-
cluding hypertension, diabetes, respiratory disease, CVD, kidney
disease, liver disease, hepatitis infection, etc. have been identified as
risks factors associated with severe disease manifestation and poor
prognosis.26,27,38 Out of 237 cases with information on comorbid-
ities, 151 (63.7%) had at least one comorbidity. Hypertension was the
most prevalent comorbidity observed in coinfected patients followed
by diabetes (Figure 4). In the original case reports included in this
study, a great part of the of the dead were reported to have multiple
comorbidities. Thus, it is possible the higher overall case‐fatality rate
reported earlier (14%) was compounded by these other comorbid-
ities and not sole contribution of HIV infection. Nevertheless, HIV
infection is generally characterized by various comorbidities 46 and
associated morbidity and mortality are inevitable.
4 | CONCLUSION
It is generally accepted that, at present, our knowledge about the
coronavirus is not definite and keeps evolving with emerging evidence,
nonetheless, the preliminary analysis of available evidence shows that
PLWH are not protected from COVID‐19 or severity of the disease.
Also, HIV‐related immunosuppression may increase risk of severity of
COVID‐19 instead confer protection. While the study does not show
excess morbidity and mortality among PLWH, especially those with
viral load suppression on ART, people living with HIV ought to be
vigilant and adhere strictly to guidelines and recommendations of how
to keep themselves safe from SARS‐CoV‐2 infection.
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